Search Medical Condition
Please enter condition
Please choose location

Head and Neck Cancer Clinical Trials

A listing of Head and Neck Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (201) clinical trials

A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer

Patients who fulfill eligibility criteria will be entered into the trial to receive ML0N128. The participant will be given a study drug-dosing diary for each treatment cycle. After the screening procedures confirm participation in the research study. - MLN0128 - Fixed doses daily per treatment cycle The treatment cycles will ...

Phase

Cisplatin Nab-Paclitaxel and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously ...

Phase

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

This is a phase 1b study, which means that the purpose of the study is to establish the maximum dose of a pill drug called BYL719, when given with a standard treatment for patients with head and neck squamous cell cancer.

Phase

Reirradiation With MK-3475 (Pembrolizumab) in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Each participant will undergo screening and then be treated with reirradiation with 1.2 Gy BID, 5 days a week (weeks 1-5). MK-3475 (generic name: pembrolizumab, trade name Keytruda®) will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued in all participants until ...

Phase

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their ...

Phase

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.

Phase

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

The primary objective of this study is to compare time to symptomatic progression (TTSP) from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry with that of asymptomatic patients with RAI-refractory progressive DTC for whom there is a ...

Phase N/A

Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer

ORCA-2 is a phase I trial in patients with locally advanced, with or without metastatic nodal disease. Patients will receive olaparib (a PARP inhibitor) in combination with standard cisplatin-based chemotherapy and intensity modulated radiotherapy (IMRT). Olaparib, cisplatin and radiotherapy will be given in combination every week for a maximum of ...

Phase

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Phase

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer Renal Cell Cancer Melanoma and Lung Cancer

PRIMARY OBJECTIVES: I. To investigate the immunomodulatory activity of radiation therapy (RT) or RT in combination with anti-programmed cell death 1 (PD)-1 antibody (MK-3475) in patients with recurrent/metastatic head and neck cancer, renal cell cancer, melanoma and lung cancer. SECONDARY OBJECTIVES: I. To explore whether programmed cell death ligand 1 ...

Phase